Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Shares Purchased by Wellington Management Group LLP

Wellington Management Group LLP grew its position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMAFree Report) by 62.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 99,121 shares of the company’s stock after purchasing an additional 38,011 shares during the period. Wellington Management Group LLP owned approximately 0.18% of Olema Pharmaceuticals worth $1,224,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of OLMA. American Century Companies Inc. raised its stake in Olema Pharmaceuticals by 188.9% during the third quarter. American Century Companies Inc. now owns 29,299 shares of the company’s stock valued at $362,000 after buying an additional 19,157 shares in the last quarter. EP Wealth Advisors LLC boosted its holdings in shares of Olema Pharmaceuticals by 831.1% during the third quarter. EP Wealth Advisors LLC now owns 46,248 shares of the company’s stock valued at $571,000 after acquiring an additional 41,281 shares during the period. Polar Capital Holdings Plc acquired a new stake in shares of Olema Pharmaceuticals in the third quarter valued at approximately $9,262,000. Jacobs Levy Equity Management Inc. raised its holdings in shares of Olema Pharmaceuticals by 226.3% during the third quarter. Jacobs Levy Equity Management Inc. now owns 244,472 shares of the company’s stock valued at $3,019,000 after buying an additional 169,553 shares during the last quarter. Finally, Public Employees Retirement System of Ohio acquired a new position in shares of Olema Pharmaceuticals during the third quarter worth approximately $35,000. 91.78% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts have weighed in on the company. Capital One Financial reaffirmed an “overweight” rating on shares of Olema Pharmaceuticals in a research note on Thursday, February 22nd. Citigroup started coverage on shares of Olema Pharmaceuticals in a research note on Tuesday, January 30th. They set a “buy” rating and a $20.00 price objective on the stock. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $21.00.

Check Out Our Latest Report on Olema Pharmaceuticals

Insider Activity

In related news, Director Cyrus Harmon sold 25,000 shares of Olema Pharmaceuticals stock in a transaction dated Thursday, February 29th. The stock was sold at an average price of $12.41, for a total transaction of $310,250.00. Following the transaction, the director now directly owns 846,283 shares of the company’s stock, valued at $10,502,372.03. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders own 23.50% of the company’s stock.

Olema Pharmaceuticals Stock Performance

Shares of NASDAQ OLMA opened at $11.32 on Friday. Olema Pharmaceuticals, Inc. has a 1 year low of $3.00 and a 1 year high of $17.79. The firm has a market cap of $633.01 million, a P/E ratio of -5.24 and a beta of 2.13. The stock has a fifty day moving average price of $13.17 and a two-hundred day moving average price of $13.12.

Olema Pharmaceuticals Company Profile

(Free Report)

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1b/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer.

See Also

Institutional Ownership by Quarter for Olema Pharmaceuticals (NASDAQ:OLMA)

Receive News & Ratings for Olema Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Olema Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.